MMTec, Inc. (NASDAQ:MTC – Get Free Report) shot up 1.6% on Monday . The stock traded as high as $0.39 and last traded at $0.39. 362,982 shares were traded during trading, a decline of 91% from the average session volume of 4,004,064 shares. The stock had previously closed at $0.38.
MMTec Trading Up 1.6 %
The firm’s fifty day moving average price is $0.36 and its two-hundred day moving average price is $0.88.
Institutional Investors Weigh In On MMTec
An institutional investor recently bought a new position in MMTec stock. Virtu Financial LLC bought a new stake in shares of MMTec, Inc. (NASDAQ:MTC – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,654 shares of the company’s stock, valued at approximately $27,000. 0.25% of the stock is owned by hedge funds and other institutional investors.
MMTec Company Profile
MMTec, Inc, together with its subsidiaries, develops and deploys platforms that enable financial institutions to engage in securities market transactions and settlements worldwide. The company operates in two segments, Gujia and MM Global. It offers Internet-based securities solutions comprising Securities Dealers Trading System, which supports securities registration and clearing, account management, risk management, trading and execution, and third party access middleware; Private Fund Investment Management System that supports multi-account management, fund valuation, risk management, quantitative trading access, liquidation, and requisition management; and Mobile Transaction Individual Client System and PC Client System for Apple IOS, Android, PC, and Web applications.
Featured Articles
- Five stocks we like better than MMTec
- What is the Australian Securities Exchange (ASX)
- Intel: Is Now the Time to Be Brave?Â
- Using the MarketBeat Dividend Tax Calculator
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for MMTec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MMTec and related companies with MarketBeat.com's FREE daily email newsletter.